PROFILE |
 |
UroMed makes and markets urological products with a primary focus on treating prostate cancer. Its two main products are the CaverMap Surgical Aid, used to map and monitor nerves during radical prostatectomy and thereby avoiding side effects such as impotence, and the Symmetra Iodine-125 seeds, used to treat localized prostate cancer. The company also sells introducer needles for use in brachytherapy, as well as Allosource Cadaveric Fascia Kits, used during surgical procedures to treat female urinary incontinence. UroMed markets its products in the US, Europe, and Japan. Philip Heintz, a director, owns more than a quarter of the company.
COMPETITION |
 |
Implant Sciences Corporation (IMX)
Rochester Medical Corporation (ROCM)
Theragenics Corporation (TGX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 4.30
1-Yr. Sales Growth: 65.7%
Employees: 54
Revenue per employee: $79,629.63
KEY PEOPLE |
 |
Daniel Muscatello
CEO
Domenic C. Micale
CFO
CONTACT INFO |
 |
1400 Providence Hwy.
Norwood, MA 02062
US
Phone: 781-762-2080
Fax: 781-762-2737
Online: Web Site
|